Clinical Trials

Myeloproliferative Disorders, Thrombocythemia, Essential, Primary Myelofibrosis

NCT06313593 2026-03-16

A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms

Phase 1 Recruiting

186 enrolled

Phase 1 Not yet recruiting

Myeloproliferative Disorders, Primary Myelofibrosis

NCT07469891 2026-03-13

A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms

100 enrolled

Classical hematologyMyeloid

Myeloproliferative Disorders, Polycythemia Vera, Primary Myelofibrosis

NCT05320198 2026-03-09

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

Phase 1/2 Recruiting

150 enrolled

Anemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Primary Myelofibrosis

NCT04877522 2026-03-06

Asciminib Roll-over Study

Phase 4 Recruiting

347 enrolled

Phase 1 Not yet recruiting

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT07441694 2026-03-02

Study of INCA036978 in Participants With Myeloproliferative Neoplasms

218 enrolled

Phase 1 Active not recruiting

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT04279847 2026-02-25

LIMBER

140 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, Recurrence, Thrombocythemia, Essential, Primary Myelofibrosis

NCT05936359 2026-02-10

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

Phase 1 Recruiting

225 enrolled

Myeloproliferative Disorders, Thrombocythemia, Essential, Primary Myelofibrosis

NCT05456191 2026-02-06

ASC4START

568 enrolled

Phase 2 Active not recruiting

Leukemia, Myeloproliferative Disorders, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04509700 2025-12-10

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

112 enrolled

LymphoidMyeloid

Lymphoma, Non-Hodgkin, Myeloproliferative Disorders

NCT04576156 2025-12-04

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

327 enrolled

Myeloproliferative Disorders, Polycythemia, Thrombocytosis, Primary Myelofibrosis

NCT03011372 2025-11-18

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

47 enrolled 21 charts 1 FDA

Eosinophilia, Myeloproliferative Disorders

NCT04064060 2025-11-12

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Phase 3 Recruiting

665 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, beta-Thalassemia

NCT00726232 2025-10-29

Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia

73 enrolled 25 charts

BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Myeloproliferative Disorders

NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Phase 1/2 Terminated

137 enrolled 31 charts

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

NCT02158858 2025-10-08

A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies

Phase 1/2 Completed

336 enrolled

MyeloidOther hematologic neoplasmOther neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Precancerous Conditions, Preleukemia, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT04562389 2025-10-03

SENTRY

353 enrolled

Myeloproliferative Disorders, Primary Myelofibrosis

NCT04551053 2025-10-02

To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

Phase 3 Terminated

177 enrolled 15 charts

Myeloproliferative Disorders, Primary Myelofibrosis

NCT04182100 2025-09-15

Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply

29 enrolled 15 charts

Myeloproliferative Disorders, Polycythemia Vera

NCT04629508 2025-09-02

To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)

4 enrolled 10 charts

Myeloproliferative Disorders, Polycythemia Vera, Thrombocytosis, Primary Myelofibrosis

NCT03952039 2025-08-28

FREEDOM2

Phase 3 Completed

202 enrolled 23 charts

Myeloproliferative Disorders, Primary Myelofibrosis

NCT04285086 2025-08-13

SURPASS ET

174 enrolled

Phase 2 Active not recruiting

Myeloproliferative Disorders, Thrombocythemia, Essential

NCT05482971 2025-08-13

A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET

91 enrolled

Myeloproliferative Disorders, Neoplasms, Thrombocythemia, Essential, Thrombocytosis

NCT06468033 2025-08-13

P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk

Phase 3 Recruiting

150 enrolled

Phase 4 Not yet recruiting

Myeloproliferative Disorders, Primary Myelofibrosis

NCT06290765 2025-07-31

PV

70 enrolled

Myeloproliferative Disorders, Polycythemia Vera

NCT05444530 2025-07-20

A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms

Phase 1 Completed

14 enrolled

Myeloproliferative Disorders

NCT04717414 2025-07-10

INDEPENDENCE

Classical hematologyMyeloid

313 enrolled

Anemia, Myeloproliferative Disorders, Primary Myelofibrosis

NCT04603001 2025-06-27

Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

Phase 1 Active not recruiting

260 enrolled

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04996875 2025-05-30

APEX

Phase 2 Recruiting

140 enrolled

Hematologic Diseases, Hypersensitivity, Immune Complex Diseases, Immune System Diseases, Leukemia, Leukemia, Mast-Cell, Leukemia, Myeloid, Mastocytosis, Myeloproliferative Disorders, Neoplasms, Neoplasms by Site, Neoplasms, Connective Tissue, Skin Diseases, Soft Tissue Neoplasms, Urticaria Pigmentosa, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Mastocytosis, Systemic

NCT01761968 2025-04-30

Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms

Phase 2 Active not recruiting

90 enrolled

Phase 1 Active not recruiting

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT04041050 2025-02-14

A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

85 enrolled

Myeloproliferative Disorders, Neoplasms, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

NCT03755518 2024-12-12

FREEDOM

Phase 3 Terminated

38 enrolled 23 charts

Myeloproliferative Disorders, Primary Myelofibrosis

NCT04655092 2024-11-08

Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients

Phase 3 Recruiting

67 enrolled

Myeloproliferative Disorders, Polycythemia Vera

NCT06002490 2024-11-08

A Study to Evaluate P1101 in Japanese PV Patients

Phase 3 Completed

21 enrolled

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Myeloproliferative Disorders, Polycythemia Vera

NCT05260203 2024-11-06

MargheRITA

Phase NA Completed

124 enrolled

Treatment Adherence and Compliance, Amyloidosis, Anemia, Refractory, with Excess of Blasts, Hodgkin Disease, Multiple Myeloma, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Neoplasms, Plasma Cell

NCT02718300 2024-05-01

A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

74 enrolled 40 charts

LymphoidMyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Hereditary Sensory and Autonomic Neuropathies, Primary Myelofibrosis

NCT05107856 2024-01-31

PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies

Phase 1 Terminated

21 enrolled

Lymphoma, Follicular, Myelodysplastic Syndromes, Myeloproliferative Disorders, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT05074550 2023-07-24

Safety Evaluation Study for Patients With Polycythemia Vera

Phase 1 Unknown

6 enrolled

Myeloproliferative Disorders, Polycythemia Vera

NCT04631211 2023-05-25

Thrombosomes® in Bleeding Thrombocytopenic Patients Study

Classical hematologyMyeloidOther hematologic neoplasm

21 enrolled

Anemia, Aplastic, Myelodysplastic Syndromes, Myeloproliferative Disorders, Thrombocytopenia, Hematologic Neoplasms

NCT04866056 2022-12-01

Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.

Phase 1/2 Terminated

1 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, Primary Myelofibrosis

NCT05612633 2022-11-10

AP-MPN

Phase 2 Withdrawn

Myeloproliferative Disorders

NCT03144687 2022-06-16

A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis

23 enrolled 31 charts

LymphoidMyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Primary Myelofibrosis

NCT01667133 2022-06-13

A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)

Phase 1/2 Completed

35 enrolled 36 charts

Bone Marrow Diseases, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Myeloid, Lymphatic Diseases, Lymphoproliferative Disorders, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04709458 2022-05-03

Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis

Phase 1 Unknown

10 enrolled

Leukemia, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Bone Marrow Neoplasms, Primary Myelofibrosis

NCT03287245 2021-12-08

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera

27 enrolled 28 charts

Hematologic Diseases, Myeloproliferative Disorders, Polycythemia Vera

NCT02627677 2021-11-26

OPTIC-2L

Phase 3 Terminated

44 enrolled 22 charts

NCT03123588 2021-11-19

Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)

12 enrolled 15 charts

Myeloproliferative Disorders, Thrombocythemia, Essential

NCT05115344 2021-11-10

Study of Flonoltinib Maleate Tablets in the Treatment of Proliferative Bone Marrow Tumors

Phase 1 Unknown

31 enrolled